-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Under the background of the continuous impact of the epidemic, industry changes and intensified competition, the adjustment of the pharmaceutical industry has entered a deep-water period
.
At present, in order to avoid the pain of adjustment period and strive for more development opportunities, various pharmaceutical companies are constantly accelerating innovation
.
Under the tide of innovation, it is very important to choose a good track.
On the whole, oncology drugs have become one of the key directions for local pharmaceutical companies to compete
.
Statistics show that the number of new drugs approved for marketing in the past five years has reached 15, accounting for more than 60%; biological drugs are concentrated in monoclonal antibodies led by PD-1
.
At present, the time has come to 2022.
According to the author's knowledge, PD-1/PD-L1 products of many companies have been approved for clinical use and marketed
.
On April 21, the NMPA website announced that the new anti-tumor drug Procarbazine Hydrochloride Capsules application submitted by Zhaoke Pharmaceutical, a subsidiary of Li's Pharmaceutical Factory, has been approved
.
According to an earlier press release issued by Lee's Big Pharma, the indication for this product's approved marketing application is: for the treatment of advanced Hodgkin's lymphoma
.
According to public information, procarbazine hydrochloride capsules were originally developed by Roche and have been approved for marketing overseas, and are produced by Leadiant Biosciences (formerly Sigma-Tau)
.
A wholly-owned subsidiary of Lee's Pharma signed a distribution agreement with Leadiant in May 2018 to promote the exclusive launch of procarbazine hydrochloride capsules in Greater China
.
On April 20, the CDE website announced that a new class 2.
4 drug named NBTXR3 has obtained an implied license for a clinical trial and is intended to be developed for the treatment of head and neck squamous cell carcinoma
.
According to public information, NBTXR3 is a novel radio-enhancer developed by Nanobiotix, which is intended for the treatment of tumors.
It consists of functionalized hafnium dioxide (HfO2) nanoparticles, which are administered via a one-time intratumoral injection and activated by radiotherapy.
.
It is understood that in May 2021, Liantuo announced a partnership with Nanobiotix to obtain the exclusive license to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore and Thailand
.
Under the agreement, LianBio will participate in a global Phase 3 head and neck cancer registration study to evaluate the efficacy of NBTXR3 in patients with locally advanced head and neck squamous cell carcinoma (HNSCC)
.
Upfront and potential milestone payments for this collaboration are up to $240 million
.
Prior to this, Sino Biopharmaceutical also announced that the group's self-developed anti-tumor class I new drug "TQB2930" for injection has been approved by the China National Medical Products Administration to conduct drug clinical trials for the treatment of patients with advanced malignant tumors
.
The data show that TQB2930 is a bispecific antibody targeting solid tumor cells, achieving a synergistic effect on the two targets
.
It blocks gene signals that drive tumor growth and kills tumor cells through a variety of mechanisms
.
Preclinical efficacy trials have shown that the molecule can significantly inhibit tumor growth
.
On the whole, under the encouragement of innovative drug policies and centralized procurement policies, the clinical research and development of innovative drugs in China is advancing rapidly
.
Among them, the field of anti-tumor drugs, as a hot disease field, is constantly making new progress
.
In the context of the acceleration of tumor drug research and development by domestic pharmaceutical companies, Essence Securities estimates that by the end of 2022, a total of 17 PD-1/PD-L1 monoclonal antibodies and 1 PD-1/CTLA-4 double antibody will be listed in China.
, of which there are 14 domestic PD-1/PD-L1 models (including double antibodies)
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
At present, in order to avoid the pain of adjustment period and strive for more development opportunities, various pharmaceutical companies are constantly accelerating innovation
.
Under the tide of innovation, it is very important to choose a good track.
On the whole, oncology drugs have become one of the key directions for local pharmaceutical companies to compete
.
Statistics show that the number of new drugs approved for marketing in the past five years has reached 15, accounting for more than 60%; biological drugs are concentrated in monoclonal antibodies led by PD-1
.
At present, the time has come to 2022.
According to the author's knowledge, PD-1/PD-L1 products of many companies have been approved for clinical use and marketed
.
On April 21, the NMPA website announced that the new anti-tumor drug Procarbazine Hydrochloride Capsules application submitted by Zhaoke Pharmaceutical, a subsidiary of Li's Pharmaceutical Factory, has been approved
.
According to an earlier press release issued by Lee's Big Pharma, the indication for this product's approved marketing application is: for the treatment of advanced Hodgkin's lymphoma
.
According to public information, procarbazine hydrochloride capsules were originally developed by Roche and have been approved for marketing overseas, and are produced by Leadiant Biosciences (formerly Sigma-Tau)
.
A wholly-owned subsidiary of Lee's Pharma signed a distribution agreement with Leadiant in May 2018 to promote the exclusive launch of procarbazine hydrochloride capsules in Greater China
.
On April 20, the CDE website announced that a new class 2.
4 drug named NBTXR3 has obtained an implied license for a clinical trial and is intended to be developed for the treatment of head and neck squamous cell carcinoma
.
According to public information, NBTXR3 is a novel radio-enhancer developed by Nanobiotix, which is intended for the treatment of tumors.
It consists of functionalized hafnium dioxide (HfO2) nanoparticles, which are administered via a one-time intratumoral injection and activated by radiotherapy.
.
It is understood that in May 2021, Liantuo announced a partnership with Nanobiotix to obtain the exclusive license to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore and Thailand
.
Under the agreement, LianBio will participate in a global Phase 3 head and neck cancer registration study to evaluate the efficacy of NBTXR3 in patients with locally advanced head and neck squamous cell carcinoma (HNSCC)
.
Upfront and potential milestone payments for this collaboration are up to $240 million
.
Prior to this, Sino Biopharmaceutical also announced that the group's self-developed anti-tumor class I new drug "TQB2930" for injection has been approved by the China National Medical Products Administration to conduct drug clinical trials for the treatment of patients with advanced malignant tumors
.
The data show that TQB2930 is a bispecific antibody targeting solid tumor cells, achieving a synergistic effect on the two targets
.
It blocks gene signals that drive tumor growth and kills tumor cells through a variety of mechanisms
.
Preclinical efficacy trials have shown that the molecule can significantly inhibit tumor growth
.
On the whole, under the encouragement of innovative drug policies and centralized procurement policies, the clinical research and development of innovative drugs in China is advancing rapidly
.
Among them, the field of anti-tumor drugs, as a hot disease field, is constantly making new progress
.
In the context of the acceleration of tumor drug research and development by domestic pharmaceutical companies, Essence Securities estimates that by the end of 2022, a total of 17 PD-1/PD-L1 monoclonal antibodies and 1 PD-1/CTLA-4 double antibody will be listed in China.
, of which there are 14 domestic PD-1/PD-L1 models (including double antibodies)
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
